| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CABIN1 |
| Uniprot No | Q9Y6J0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CABIN1重组蛋白的假设性参考文献示例(实际文献需通过学术数据库查询)：
---
1. **文献名称**: *CABIN1 Recombinant Protein Suppresses T-cell Activation by Inhibiting Calcineurin Signaling*
**作者**: Tanaka, M. et al.
**摘要**: 本研究利用大肠杆菌表达系统纯化CABIN1重组蛋白，发现其通过结合钙调磷酸酶(calcineurin)抑制其磷酸酶活性，从而阻断NFAT信号通路，导致T细胞活化受阻。体外实验证实重组CABIN1可抑制抗原诱导的IL-2分泌。
2. **文献名称**: *Structural Characterization of the CABIN1-Calcium Complex by Cryo-EM*
**作者**: Liu, X. & Wei, H.
**摘要**: 通过冷冻电镜解析CABIN1重组蛋白的钙离子结合结构域，揭示了其与calcineurin相互作用的关键区域。研究为设计靶向CABIN1-calcium信号通路的免疫调节药物提供了结构基础。
3. **文献名称**: *CABIN1 Recombinant Protein Enhances Apoptosis in Cancer Cells via p53 Pathway*
**作者**: Gupta, R. et al.
**摘要**: 研究发现，外源性添加CABIN1重组蛋白可促进肿瘤细胞凋亡，机制涉及稳定p53蛋白并增强其转录活性。实验表明CABIN1可能作为潜在抗癌治疗的辅助分子。
4. **文献名称**: *Expression and Purification of Functional CABIN1 in Mammalian Cells for Drug Screening*
**作者**: Park, J. et al.
**摘要**: 开发了一种基于HEK293细胞的CABIN1重组蛋白表达系统，优化纯化条件后获得高活性蛋白。该蛋白成功用于高通量筛选靶向CABIN1-calcineurin相互作用的小分子抑制剂。
---
**注意**：以上文献为示例性内容，实际研究中请通过 **PubMed、Google Scholar** 或 **Web of Science** 检索真实文献(关键词：CABIN1 recombinant protein, calcineurin inhibitor, T-cell signaling)。真实研究可能侧重于CABIN1在自身免疫疾病、癌症或神经退行性疾病中的作用机制。
CABIN1 (calcineurin-binding protein 1), also known as CAIN or CARP, is a multifunctional scaffold protein involved in regulating calcium-dependent signaling pathways, particularly through its interaction with calcineurin (a calcium/calmodulin-dependent phosphatase). It was initially identified as a calcineurin inhibitor that suppresses T-cell receptor signaling and immune responses by blocking calcineurin-mediated dephosphorylation of nuclear factor of activated T cells (NFAT). Beyond immune regulation, CABIN1 participates in diverse cellular processes, including cell cycle progression, apoptosis, chromatin remodeling, and transcriptional regulation, through interactions with proteins like MEF2. p53. and histone deacetylases (HDACs).
The recombinant CABIN1 protein is engineered for in vitro studies to dissect its structural and functional properties. It typically includes key domains, such as the N-terminal calcineurin-binding region and C-terminal chromatin-modifying motifs, enabling researchers to explore its dual roles as a signaling modulator and epigenetic regulator. Recombinant CABIN1 is widely used to study calcineurin/NFAT pathway inhibition, which has implications in autoimmune diseases, cardiac hypertrophy, and neurological disorders. Additionally, it aids in investigating CABIN1’s tumor-suppressive functions, as its downregulation is linked to cancer progression via dysregulated apoptosis and cell cycle checkpoints.
Produced in systems like *E. coli* or mammalian cells, recombinant CABIN1 retains post-translational modifications critical for its activity in certain applications. Its utility spans biochemical assays (e.g., phosphatase activity inhibition), protein interaction mapping, and cellular pathway modulation experiments. Recent studies also highlight its potential as a therapeutic target, particularly in diseases driven by calcineurin hyperactivity or epigenetic dysregulation. Overall, recombinant CABIN1 serves as a vital tool for unraveling its complex biology and translational relevance.
×
